Who founded Glyphic Biotechnologies?

Glyphic Biotechnologies was founded by Daniel Estandian, Ed Boyden, Josh Yang in 2021.

Who are Glyphic Biotechnologies's investors?

Glyphic Biotechnologies's investors include Artis Ventures, Black Flag, Civilization Ventures Management, Llc, FoundersX Ventures, Harpoon Ventures, LongeVC, Modi Ventures, OMX Ventures and 4 more.

How much funding has Glyphic Biotechnologies raised?

Glyphic Biotechnologies has disclosed $33.2M raised across 1 round.

Where is Glyphic Biotechnologies headquartered?

Glyphic Biotechnologies is headquartered in Berkeley, US.

Glyphic Biotechnologies

Berkeley, US · Founded 2021 · Delaware corporation · 35 employees on LinkedIn · 12 known investors

Find your way into Glyphic Biotechnologies

983 people in our graph share verified history with the Glyphic Biotechnologies team — schools, employers, funds. One of them is your warm intro.

Scott Davisunlockedknows Daniel Estandian · together at University of California, Berkeley (overlapped)

×5knows the team · via Stealth Startup

×4knows the team · via University of California, Berkeley

×2knows the team · via Massachusetts Institute of Technology

Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.

Biotech Deep Tech

Founders & leadership

Glyphic Biotechnologies was founded in 2021 by Daniel Estandian, Ed Boyden, and Josh Yang.

Daniel Estandian inCTO - Technical Founder2021–2024Daniel Estandian holds a PhD from MIT and previously served as Technical Founder and CTO/CSO of Glyphic Biotechnologies, where he developed high-throughput single-molecule protein sequencing technology. He has expertise in chemistry, neuroscience, and molecular biology, and currently works on technology to address microplastics and industrial pollutants.

Ed BoydenFounder

Josh YanginFounder, CEO, and Board Member

Board

Craig Asher in 𝕏Board MemberManaging Director at OMX Ventures

Jimmy YunBoard director

Investors · 12

Artis VenturesSan Francisco · $50K – $25M

Black FlagSan Diego · $100K – $1M

Civilization Ventures Management, LlcTiburon · $1M – $10M

FoundersX VenturesSilicon Valley

Harpoon VenturesSan Diego · $100K – $5M

LongeVCWashington D.C.

Modi VenturesHouston

OMX VenturesLincolnshire

WingPalo Alto · $200K – $20M

Axial VCreportedSan Francisco · $100K – $5M

Cantos VenturesreportedSan Francisco · $400K – $1.5M

GENERAL INCEPTIONreportedPalo Alto

Reported raises · per SEC filings

Form D private placements

$33.2M disclosed across 1 round · 2024

▶$33.2MraisedFeb 2024 · 37 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joshua YangExecutive Officer, Director
Craig AsherDirector
Jimmy YunDirector
Daniel EstandianExecutive Officer, Director

Offering amount: $52.9M
Amount sold: $33.2M
First sale: Feb 2024
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Peptilogics7 shared keywordsPeptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

Macrogenics Inc7 shared keywordsMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.

Companies competing with Glyphic Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$408.9K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$390.6K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$359K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$409.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Glyphic Biotechnologies do?: Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.
Who founded Glyphic Biotechnologies?: Glyphic Biotechnologies was founded by Daniel Estandian, Ed Boyden, Josh Yang in 2021.
Who are Glyphic Biotechnologies's investors?: Glyphic Biotechnologies's investors include Artis Ventures, Black Flag, Civilization Ventures Management, Llc, FoundersX Ventures, Harpoon Ventures, LongeVC, Modi Ventures, OMX Ventures and 4 more.
How much funding has Glyphic Biotechnologies raised?: Glyphic Biotechnologies has disclosed $33.2M raised across 1 round.
Where is Glyphic Biotechnologies headquartered?: Glyphic Biotechnologies is headquartered in Berkeley, US.